Clinical Trials on H7N9 Influenza

Total 2317 results

University Hospital, Ghent
GlaxoSmithKline; Novartis Vaccines; University of Surrey; Innovative Medicines... and other collaborators

Completed

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Safety Markers of Adjuvanted Influenza Vaccine

Belgium
University of Alberta

Completed

Influenza Virus - A Multicenter Registry

Influenza Infection in Transplant Patients

Canada
University Hospital, Saarland
Klinikum Worms

Completed

Realization of the Recommendation for Influenza Vaccination in Pregnant Women

Coverage Rate of Vaccination for Influenza
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Saad Jamshed MD
Sanofi

Completed

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy (IMMUNE)

Cancer | Influenza Viral Infections

United States
Service de Médecine Préventive Hospitalière

Completed

Promotion of Influenza Vaccination in Healthcare Workers During the Recruitment Visit

Human Influenza Vaccination in Healthcare Workers
University of Pittsburgh
Merck Sharp & Dohme LLC; Pfizer

Completed

4 Pillars Toolkit for Adolescent Vaccination

Adolescent HPV Vaccine | Adolescent Influenza Vaccine

United States
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
BioCryst Pharmaceuticals

Completed

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

Acute, Uncomplicated Human Influenza

United States, Australia, New Zealand, South Africa
Chiltern Pesquisa Clinica Ltda

Completed

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

H1N1 Influenza Virus | Invasive Solid Tumors

Brazil
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

H1N1 Influenza Virus

United States
UMN Pharma Inc.

Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Virus Diseases | Influenza

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

India
Aptitude Medical Systems
Biomedical Advanced Research and Development Authority

Recruiting

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

SARS-CoV-2 Infection | Influenza A | Influenza B

United States
DiaSorin Molecular LLC

Completed

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

Coronavirus Disease 2019 | Influenza A | Influenza Type B

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Celltrion

Terminated

A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Influenza A

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
Fundacio d'Investigacio en Atencio Primaria Jordi...

Completed

Effectiveness of a Brief Intervention for Acceptance of Influenza Vaccine in the Primary Care Setting

Health Education | Influenza Vaccination

Spain
National Institute of Allergy and Infectious Diseases...

Completed

Blood and Plasma Collection For Use in Future Clinical Trials

Influenza A Virus Infection

United States
Genentech, Inc.

Completed

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Influenza A

United States, Spain, Korea, Republic of, United Kingdom, Canada, New Zealand, South Africa
Public Health England
Institute of Child Health

Completed

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™). (LAIV Immuno)

Live Attenuated Influenza Vaccine

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Pre-pandemic Influenza Vaccine

Czech Republic
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60

Quadrivalent Influenza Virus Vaccine
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States
University of British Columbia

Completed

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Influenza Vaccination in Seniors

Canada
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Priming and Boosting Strategies

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With MF59

Influenza

United States
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents

Influenza, Human | Novel 2009 Influenza H1N1

Hungary
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

Influenza

United States
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
Sungkyunkwan University
Government-wide R&D Fund project for infectious disease research (GFID)

Unknown

Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy

Pregnancy Related | Influenza Virus Vaccine Adverse Reaction
The Jackson Laboratory
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults (FluVax3)

Aging | Influenza Vaccine | Vaccine Response | Dendritic Cell

United States
Advocate Health Care

Completed

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

Influenza | Malignancy | Influenza Virus Vaccine Adverse Reaction (Disorder)
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Assistance Publique - Hôpitaux de Paris

Recruiting

Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician (GP-FluRecall)

Influenza Viral Infections

France
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

Influenza Vaccine | Cost-Benefit Analysis

Italy
Pneumagen Ltd.

Completed

Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

Influenza Viral Infections

United Kingdom
Imperial College London
Public Health England

Completed

Efficacy & Safety of Nasal Influenza Immunisation in Children (SNIFFLE-3)

Influenza Vaccines Efficacy and Safety

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

Influenza | Swine-origin A/H1N1 Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

Prophylaxis of A/H3N2v Influenza

United States
Radboud University Medical Center

Completed

Effects of BCG on Influenza Induced Immune Response

Trained Immunity | Influenza Virus Infection

Netherlands

Clinical Trials on H7N9 Influenza

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations